SUTENT has been proven effective in the treatment of GIST in certain patients†
A clinical trial proved that SUTENT is an effective treatment for certain patients with GIST.†
4 times the number of months without tumor growth
Patients treated with SUTENT lived 4 times the number of months without tumor growth compared to patients given a placebo.
The data represent a median. SUTENT is not a cure and not all patients will experience the same results.
†SUTENT is used to treat GIST (gastrointestinal stromal tumor). This is a rare cancer of the stomach, bowel, or esophagus. SUTENT is used when the medicine Gleevec® (imatinib mesylate) did not stop the cancer from growing, or when you cannot take Gleevec. Gleevec is a registered trademark of Novartis AG.